Ritlecitinib (Litfulo) for Severe Alopecia Areata
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1690a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
The FDA has approved ritlecitinib (Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug to be approved in the US for treatment of severe alopecia areata; baricitinib (Olumiant), a JAK inhibitor, is approved only for use in adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Ritlecitinib (Litfulo) for Severe Alopecia Areata. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1690a
Vancouver
Ritlecitinib (Litfulo) for Severe Alopecia Areata. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1690a
BibTeX
@article{euvimed2023,
title = {Ritlecitinib (Litfulo) for Severe Alopecia Areata},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1690a}
}
EUVIMED